The STOP-HF study used a BNP-guided strategy to further investigate and manage subclinical LVD in asymptomatic people aged over 40 years with at least 1 risk factor for HF (only 20% had T2DM) [5]. The gene discussed is NPPB; the disease is hydrops fetalis.